A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

May 25, 2011

Higher Risk of Cirrhosis in HIV/HCV Patients With 'Good' IL-28B Gene Variant

A genetic mutation that typically improves the chances of being cured of hep C using a treatment regimen than contains interferon may actually increase the risk of serious liver scarring (cirrhosis) in people coinfected with HIV, according to a report published in the June 1 issue of The Journal of Infectious Diseases (JID). This finding appears to be unique among HIV/HCV-coinfected patients; similar findings have not been documented in people living with HCV but not HIV.

Interleukin 28B (IL-28B) is a human gene that plays a role in the immune system’s defense against certain viruses. Recently discovered changes, or polymorphisms, in the gene have been linked to higher (or lower) rates of spontaneous clearance of HCV during the first six months of infection, as well as cure rates in people with HCV genotype 1—one of the hardest-to-treat forms of the virus—using one of the most important drugs used to treat hepatitis C: pegylated interferon alpha. People with the “CC” IL-28B polymorphism, which is more common in whites, are two- to three-times more likely to be cured of their HCV with a treatment regimen consisting of pegylated interferon and ribavirin, compared with those who have either the “CT” or “TT” IL-28B type.

It has also been suggested that the CC IL-28B polymorphism is less likely to be associated with the development of advanced liver scarring, according to at least one study looking at the prevalence of the CC, CT or TT polymorphisms in people living with HCV (but not HIV) who developed cirrhosis. 

The opposite appears to be true in people coinfected with HIV and HCV, according to the JID paper authored by Pablo Barreiro, MD, PhD, of the Hospital Carlos III in Madrid and his colleagues. 

The study enrolled 304 HIV/HCV coinfected patients, all of whom underwent Fibroscan testing—a noninvasive technique of measuring liver stiffness—and IL-28B testing. While most patients were receiving antiretroviral therapy for their HIV, none had been treated for hepatitis C.  Sixty-eight percent of the patients had HCV genotypes 1 or 4, another form of the virus that remains difficult to treat.

Forty-six percent of the patients had the CC IL-28B polymorphism, whereas 43 and 11 percent had the CT and TT IL-28B polymorphisms, respectively.

Cirrhosis was documented in 24 percent of the CC carriers, compared with 13 percent of the CT and TT carriers combined. In fact, compared with other risk factors—such as older age and alcohol use—IL-28B genotype was, statistically speaking, the single most important risk factor for cirrhosis in the coinfected patients.

Barreiro and his colleagues also documented that volunteers with the CC IL-28B polymorphism appeared to progress faster to liver cirrhosis than their peers with either the CT or TT IL-28B genotype.

“The IL-28B…CC genotype is associated with a higher prevalence of cirrhosis in HIV-HCV–coinfected patients than CT/TT genotypes,” the authors conclude, “suggesting that IL-28B CC carriers may experience a more rapid progression of HCV-related liver fibrosis, perhaps as [a] result of increased liver inflammation. Thus, access to HCV treatment is of utmost importance in IL-28B CC carriers, in whom treatment response is better and in whom progression to cirrhosis might occur more rapidly.”

Search: IL-28B, hepatitis C, HCV, polymorphism, cirrhosis, coinfection, Barreiro, Hospital Carlos III, Madrid


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter


Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.